* Edgewise Therapeutics Inc EWTX.OQ reported a quarterly
adjusted loss of 33 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -36 cents. The mean expectation of six analysts
for the quarter was for a loss of 39 cents per share. Wall
Street expected results to range from -49 cents to -28 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Edgewise Therapeutics Inc's reported EPS for the quarter
was a
loss of 33 cents.
* The company reported a quarterly loss of $28.53 million.
* Edgewise Therapeutics Inc shares had risen by 14.5% this
quarter and gained 91.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 12.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $29.00
This summary was machine generated from LSEG data May 9 at 02:14
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.39 -0.33 Beat
Dec. 31 2023 -0.43 -0.47 Missed
Sep. 30 2023 -0.40 -0.41 Missed
Jun. 30 2023 -0.40 -0.34 Beat